Preclinical studies [8] as well as first observational studies in patients with MEN1 [9] suggest that somatostatin analogues (SSA) might be effective for primary and secondary prevention of MEN1-associated pancreatic NEN. This evidence concerns the gene MEN1 and pancreatic neuroendocrine neoplasm.